Nov 02, 2022
Immutep to Participate in Two Upcoming Investor Conferences
Nov 01, 2022
Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Oct 25, 2022
Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned
Immutep Quarterly Activities Report
Oct 04, 2022
Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Oct 03, 2022
Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer
Sep 26, 2022
Sep 22, 2022
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
Sep 13, 2022
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
Sep 12, 2022
Immutep Appoints LAG-3 Pioneer, Dr Frédéric Triebel to Board
Sep 05, 2022
Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma
Aug 29, 2022
Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor
